Clinical trial NCT01989819: Primary Sjögren Syndrome
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Primary Sjögren's Syndrome
Lead sponsor: University Hospital, Limoges
Sponsor class: OTHER
First posted: 2013-11-21
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Sjögren's syndrome

Brief summary: Primary Sjögren syndrome (pSS) is an inflammatory, autoimmune, multiorgan disease often involving the central and peripheral nervous systems. Fifteen to twenty percent of patients with the primary Sjögren's syndrome have neurological complications involving the peripheral nervous system. Although some patients have large fiber neuropathy, around forty percent of patients with Sjögren's syndrome experience neuropathic pain with normal electrodiagnostic studies. Although these patients may be diagnosed with fibromyalgia or depressive symptoms, some have been shown to have small fiber neuropathy (SFN). A recent study proved that more than 90% of pSS patients with such neuropathic pain have SFN {Fauchais, 2010 #188}.

The aim of this study will be to investigate the occurrence of small fiber neuropathy in patients with pSS and neuropathic pain with normal electromyographic studies and to determine the existence of a conjoint local inflammatory process mediated by cellular, cytokinic or auto-antibody response. Quantification of epidermal nerve fiber density after skin biopsy is a valuable tool to diagnose small fiber neuropathy and the method has been widely validated. A skin biopsy will be performed in patients and control and will allow quantification of small fiber density in skin sample along with measurement of sweat gland innervation. Moreover, pathophysiological studies will be carried on in order to evaluate the causal relationship between cellular and humoral inflammation and small fiberneuropathy.

Recent studies have pointed out the inconstant efficacy of both corticosteroid and immunosuppressive drugs in pSS-related SFN. Dissecting the molecular mechanisms of small fiber neuropathy in these patients may help designing new therapeutic strategies.


Eligibility criteria: Inclusion Criteria:

* Patients with pSS according to revised European criteria and exhibiting neuropathic pain without any electromyographic abnormality will be included (Group I).
* Age of entry into the study ≥ 18 yrs (both groups).
* Affiliated or profit patient of a social security system (both groups).
* Informed consent signed up (both groups).

Exclusion Criteria:

* Chronic alcoholism
* Type I or type II diabetes
* Peripheral neuropathy unrelated to pSS complications
* Coagulation disease
* Previous allergy to xylocaine, lidocaine, prilocaine or ricin oil
* Porphyria, methemoglobinemia
* Patients under measure of maintenance of justice.
* Patients unable to understand or to participate to the study.
* Child and major patients making the object of a measure of lawful protection.
* Patients deprived of freedom.
* Pregnant, nursing women.
* Participation in biomedical research within one month prior to inclusion.

Primary outcomes:
measure: To evaluate the cutaneous lymphocytic infiltration
timeFrame: 1 year
Secondary outcomes:
measure: Cutaneous infiltration T, B and Th17
timeFrame: 1 year
Other outcomes:
Locations:
city: Albi
country: France
facility: CH d'Albi
city: Bordeaux
country: France
facility: CHU Bordeaux
city: Brive la Gaillarde
country: France
facility: CH de Brive
city: Lille
country: France
facility: CHU de Lille
city: Limoges
country: France
facility: University Hospital, Limoges
city: Rodez
country: France
facility: CH de Rodez
city: Toulouse
country: France
facility: CHU Toulouse
Study officials:
affiliation: University Hospital, Limoges
name: Anne-Laure FAUCHAIS, MD
role: PRINCIPAL_INVESTIGATOR
References: